{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T16:36:14Z","timestamp":1776702974677,"version":"3.51.2"},"reference-count":36,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,7]],"date-time":"2022-12-07T00:00:00Z","timestamp":1670371200000},"content-version":"vor","delay-in-days":2593,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001826","name":"Netherlands Organisation for Health Research and Development","doi-asserted-by":"publisher","award":["916.13.078"],"award-info":[{"award-number":["916.13.078"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001826","name":"Netherlands Organisation for Health Research and Development","doi-asserted-by":"publisher","award":["916.76.023"],"award-info":[{"award-number":["916.76.023"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001826","name":"Netherlands Organisation for Health Research and Development","doi-asserted-by":"publisher","award":["016.116.358"],"award-info":[{"award-number":["016.116.358"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003180","name":"Academisch Medisch Centrum","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003180","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1111\/jth.13132","type":"journal-article","created":{"date-parts":[[2015,9,4]],"date-time":"2015-09-04T11:22:15Z","timestamp":1441365735000},"page":"2076-2086","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Thrombin\u2010activatable fibrinolysis inhibitor influences disease severity in humans and mice with pneumococcal meningitis"],"prefix":"10.1016","volume":"13","author":[{"given":"B.B.","family":"Mook\u2010Kanamori","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Valls Ser\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Geldhoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.R.","family":"Havik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"van der Ende","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Baas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"van der Poll","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.C.M.","family":"Meijers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"P. Morgan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.C.","family":"Brouwer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"van de Beek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1111\/jth.13132_bb0010","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1056\/NEJMoa040845","article-title":"Clinical features and prognostic factors in adults with bacterial meningitis","volume":"351","author":"van de Beek","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.13132_bb0015","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1086\/344229","article-title":"Cognitive impairment in adults with good recovery after bacterial meningitis","volume":"186","author":"van de Beek","year":"2002","journal-title":"J Infect Dis"},{"key":"10.1111\/jth.13132_bb0020","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1111\/j.1469-0691.2011.03668.x","article-title":"Hearing loss in adults surviving pneumococcal meningitis is associated with otitis and pneumococcal serotype","volume":"18","author":"Heckenberg","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"10.1111\/jth.13132_bb0025","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1128\/CMR.00008-11","article-title":"Pathogenesis and pathophysiology of pneumococcal meningitis","volume":"24","author":"Mook\u2010Kanamori","year":"2011","journal-title":"Clin Microbiol Rev"},{"key":"10.1111\/jth.13132_bb0030","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s12028-011-9634-4","article-title":"Cerebral infarction in adults with bacterial meningitis","volume":"16","author":"Schut","year":"2011","journal-title":"Neurocrit Care"},{"key":"10.1111\/jth.13132_bb0035","doi-asserted-by":"crossref","first-page":"e45271","DOI":"10.1371\/journal.pone.0045271","article-title":"Intracerebral hemorrhages in adults with community associated bacterial meningitis in adults: should we reconsider anticoagulant therapy?","volume":"7","author":"Mook\u2010Kanamori","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1111\/jth.13132_bb0040","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/S1473-3099(10)70045-1","article-title":"Host genetics and outcome in meningococcal disease: a systematic review and meta\u2010analysis","volume":"10","author":"Brouwer","year":"2010","journal-title":"Lancet Infect Dis"},{"key":"10.1111\/jth.13132_bb0045","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.2174\/138955709789055216","article-title":"Recent developments in thrombin\u2010activatable fibrinolysis inhibitor research","volume":"9","author":"Marx","year":"2009","journal-title":"Mini Rev Med Chem"},{"key":"10.1111\/jth.13132_bb0050","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/s11239-011-0676-4","article-title":"Thrombin\u2010activatable fibrinolysis inhibitor is activated in vivo in a baboon model of Escherichia coli induced sepsis","volume":"33","author":"Kim","year":"2012","journal-title":"J Thromb Thrombolysis"},{"key":"10.1111\/jth.13132_bb0055","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/j.1348-0421.2002.tb02669.x","article-title":"Inactivation of C3a and C5a octapeptides by carboxypeptidase R and carboxypeptidase N","volume":"46","author":"Campbell","year":"2002","journal-title":"Microbiol Immunol"},{"key":"10.1111\/jth.13132_bb0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0049-3848(01)00331-0","article-title":"Activity and antigen levels of thrombin\u2010activatable fibrinolysis inhibitor in plasma of patients with disseminated intravascular coagulation","volume":"104","author":"Watanabe","year":"2001","journal-title":"Thromb Res"},{"key":"10.1111\/jth.13132_bb0065","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1159\/000093109","article-title":"Evolution of thrombin formation and fibrinolysis markers, including thrombin\u2010activatable fibrinolysis inhibitor, during severe meningococcemia","volume":"34","author":"Fouassier","year":"2005","journal-title":"Pathophysiol Haemost Thromb"},{"key":"10.1111\/jth.13132_bb0070","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.thromres.2005.06.007","article-title":"TAFI and PAI\u20101 levels in human sepsis","volume":"118","author":"Zeerleder","year":"2006","journal-title":"Thromb Res"},{"key":"10.1111\/jth.13132_bb0075","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1538-7836.2008.02841.x","article-title":"Thrombin\u2010activatable fibrinolysis inhibitor is associated with severity and outcome of severe meningococcal infection in children","volume":"6","author":"Emonts","year":"2008","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.13132_bb0080","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s00277-005-1079-4","article-title":"Plasma antigen levels of thrombin\u2010activatable fibrinolysis inhibitor did not differ in patients with or without disseminated intravascular coagulation","volume":"84","author":"Chen","year":"2005","journal-title":"Ann Hematol"},{"key":"10.1111\/jth.13132_bb0085","doi-asserted-by":"crossref","first-page":"6764","DOI":"10.4049\/jimmunol.175.10.6764","article-title":"Absence of thrombin\u2010activatable fibrinolysis inhibitor protects against sepsis\u2010induced liver injury in mice","volume":"175","author":"Renckens","year":"2005","journal-title":"J Immunol"},{"key":"10.1111\/jth.13132_bb0090","doi-asserted-by":"crossref","first-page":"3943","DOI":"10.1172\/JCI57522","article-title":"Complement component 5 contributes to poor disease outcome in humans and mice with pneumococcal meningitis","volume":"121","author":"Woehrl","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1111\/jth.13132_bb0095","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/S0140-6736(76)92215-7","article-title":"Predicting outcome in individual patients after severe head injury","volume":"1","author":"Jennett","year":"1976","journal-title":"Lancet"},{"key":"10.1111\/jth.13132_bb0100","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s00401-013-1216-4","article-title":"Plasminogen activator inhibitor\u20101 influences cerebrovascular complications and death in pneumococcal meningitis","volume":"127","author":"Brouwer","year":"2014","journal-title":"Acta Neuropathol"},{"key":"10.1111\/jth.13132_bb0105","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.jinf.2012.07.001","article-title":"Genetic variation in GLCCI1 and dexamethasone in bacterial meningitis","volume":"65","author":"Brouwer","year":"2012","journal-title":"J Infect"},{"key":"10.1111\/jth.13132_bb0110","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s00251-012-0653-x","article-title":"Genetic variation in inflammasome genes is associated with outcome in bacterial meningitis","volume":"65","author":"Geldhoff","year":"2013","journal-title":"Immunogenetics"},{"key":"10.1111\/jth.13132_bb0115","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1055\/s-0037-1615366","article-title":"Plasma TAFI levels influence the clot lysis time in healthy individuals in the presence of an intact intrinsic pathway of coagulation","volume":"80","author":"Mosnier","year":"1998","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.13132_bb0120","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/1471-2334-12-71","article-title":"Characterization of a pneumococcal meningitis mouse model","volume":"12","author":"Mook\u2010Kanamori","year":"2012","journal-title":"BMC Infect Dis"},{"key":"10.1111\/jth.13132_bb0125","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1046\/j.1538-7836.2003.00404.x","article-title":"Impaired healing of cutaneous wounds and colonic anastomoses in mice lacking thrombin\u2010activatable fibrinolysis inhibitor","volume":"1","author":"te Velde","year":"2003","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.13132_bb0130","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1111\/j.1538-7836.2010.04014.x","article-title":"Thrombin\u2010activatable fibrinolysis inhibitor is degraded by Salmonella enterica and Yersinia pestis","volume":"8","author":"Valls Ser\u00f3n","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.13132_bb0135","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1538-7836.2004.00557.x","article-title":"A functional single nucleotide polymorphism in the thrombin\u2010activatable fibrinolysis inhibitor (TAFI) gene associates with outcome of meningococcal disease","volume":"2","author":"Kremer Hovinga","year":"2004","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.13132_bb0140","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1074\/jbc.M104444200","article-title":"Two naturally occurring variants of TAFI (Thr\u2010325 and Ile\u2010325) differ substantially with respect to thermal stability and antifibrinolytic activity of the enzyme","volume":"277","author":"Schneider","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1111\/jth.13132_bb0145","first-page":"3517","article-title":"Plasma carboxypeptidase B downregulates inflammatory responses in autoimmune arthritis","volume":"121","author":"Song","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1111\/jth.13132_bb0150","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1160\/TH04-08-0497","article-title":"Quantification of thrombin activatable fibrinolysis inhibitor (TAFI) gene polymorphism effects on plasma levels of TAFI measured with assays insensitive to isoform\u2010dependent artefact","volume":"94","author":"Fr\u00e8re","year":"2005","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.13132_bb0155","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1182\/blood.V97.7.2053","article-title":"Identification of polymorphisms in the promoter and the 3\u2032 region of the TAFI gene: evidence that plasma TAFI antigen levels are strongly genetically controlled","volume":"97","author":"Henry","year":"2001","journal-title":"Blood"},{"key":"10.1111\/jth.13132_bb0160","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.thromres.2009.01.005","article-title":"Procarboxypeptidase U (TAFI) contributes to the risk of thrombosis in patients with hereditary thrombophilia","volume":"124","author":"Heylen","year":"2009","journal-title":"Thromb Res"},{"key":"10.1111\/jth.13132_bb0165","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1160\/TH06-07-0407","article-title":"Genetic variation in thrombin\u2010activatable fibrinolysis inhibitor (TAFI) is associated with the risk of splanchnic vein thrombosis","volume":"97","author":"de Bruijne","year":"2007","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.13132_bb0170","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.thromres.2009.07.004","article-title":"Thrombin\u2010activatable fibrinolysis inhibitor genetic polymorphisms as markers of the type of acute coronary syndrome","volume":"124","author":"T\u00e0ssies","year":"2009","journal-title":"Thromb Res"},{"key":"10.1111\/jth.13132_bb0175","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1111\/j.1538-7836.2009.03350.x","article-title":"The role of thrombin activatable fibrinolysis inhibitor in arterial thrombosis at a young age: the ATTAC study","volume":"7","author":"de Bruijne","year":"2009","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.13132_bb0180","doi-asserted-by":"crossref","first-page":"e3615","DOI":"10.1371\/journal.pone.0003615","article-title":"Gender differences in genetic risk profiles for cardiovascular disease","volume":"3","author":"Silander","year":"2008","journal-title":"PLoS ONE"},{"key":"10.1111\/jth.13132_bb0185","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1111\/j.1538-7836.2010.03787.x","article-title":"What has been learnt from the thrombin\u2010activatable fibrinolysis inhibitor\u2010deficient mouse?","volume":"8","author":"Morser","year":"2010","journal-title":"J Thromb Haemost"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjth.13132","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjth.13132","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622086901?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622086901?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/jth.13132\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T03:10:44Z","timestamp":1761534644000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783622086901"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11]]},"references-count":36,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["S1538783622086901"],"URL":"https:\/\/doi.org\/10.1111\/jth.13132","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2015,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Thrombin\u2010activatable fibrinolysis inhibitor influences disease severity in humans and mice with pneumococcal meningitis","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/jth.13132","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}